01
Fast-Growing Market
Global peptide therapeutics projected to reach US $100B by 2034 (8.1% CAGR), with a structural gap in regulated supply and clinical evidence.
PEPTIDE DEVELOPMENT LABS INC. · DEVELOPMENT STAGE
Advancing injectable peptide candidates through regulated drug development
We build the GMP supply, regulatory strategy and physician-led access that turn fragmented injectable peptide demand into structured clinical development.
LEAD CANDIDATE
VELEMPEX™
Subcutaneous BPC-157 · refractory ligament disorders
QUALIFIED PARTNER NETWORK
Every step of the chain runs through a qualified partner
API supply, sterile fill-finish, delivery device, analytical release and physician access - each held to GMP and documented end to end.
INVESTMENT HIGHLIGHTS
Why PDL is positioned to lead regulated injectable peptide development
Much of today's injectable peptide use occurs with unauthorized molecules through illicit channels. PDL steps into that gap with a fully GMP-compliant, physician-led platform.
02
De-Risked Operating Base
Pharmaceutical-grade GMP supply chain, SOPs, supplier and CMO oversight, traceability, and Health Canada-facing systems already in place.
OPERATING BASE
~5.5 years and ~$8.5M already invested
03
Speed to Market
PDL starts with the GMP, quality and regulatory foundation competitors spend ~2 years and ~$8.5M to assemble - compressing time to clinic.
04
Canada-First Strategy
Dual-track SAP and CTA pathway aligned with EMA / FDA principles - preserving DIN and IND optionality.
05
Repeatable Peptide Platform
GMP, quality, distribution, physician network and data engine ready to scale beyond VELEMPEX™ to additional candidates.
06
VELEMPEX™ Lead Asset
Subcutaneous BPC-157 for refractory ligament disorders - physician-led access via a Canadian GMP-certified sterile CMO, and the first proof point for a repeatable platform.
See the pipeline →DEVELOPMENT ROADMAP
From API qualification to first patient
-
JUN – JUL 2026
IN PROGRESS
Qualification & setup
- ▪Canadian sterile fill-and-finish CMO
- ▪Supplier controls & stability program
- ▪Prefilled delivery device
- ▪BPC-157 API supplier
-
AUG – NOV 2026
NEXT
Validation
- ▪API imported to Canadian CMO
- ▪First validation result reported
- ▪Second validation result reported
-
DEC 26 – MAR 27
PLANNED
Licensing
- ▪First GMP API batches
- ▪GMP material delivered to CMO
- ▪Drug Establishment Licence issued
- ▪Delivery device announced
-
APR – MAY 2027
TARGET
Clinical access
- ▪First GMP batch released
- ▪First SAP request & patient treated
- ▪CTA filed with Health Canada
NEWS & DISCLOSURE
Latest news releases
Peptide Development Labs announces proposed listing on the Canadian Securities Exchange
Placeholder release - final wording and date pending closing of the financing and exchange approval. This slot carries the company's most significant disclosure.
Read release →PDL qualifies Canadian sterile fill-and-finish CMO for its BPC-157 candidate
Placeholder - Phase 1 qualification milestone.
Company outlines Canada-first SAP and CTA regulatory strategy
Placeholder - regulatory disclosure as milestones are reached.
PDL appoints leadership team and announces formation of the company
Placeholder - founding announcement.